Renal artery stenosis / ischaemic nephropathy (renovascular disease)
Bedside summary
Narrowing of one or both renal arteries reducing renal perfusion and activating the renin-angiotensin system. Two main causes: atherosclerotic (older patients, diffuse vascular disease, ostial lesions — commonest) and fibromuscular dysplasia (younger women, mid/distal artery 'string of beads'). Causes secondary/resistant hypertension, 'flash' pulmonary oedema, and ischaemic nephropathy (progressive CKD). A characteristic clue is a significant rise in creatinine after starting an ACEi/ARB (loss of efferent arteriolar tone in a perfusion-dependent kidney, especially bilateral disease). Medical therapy is the default; revascularisation is reserved for selected refractory cases.
Red flags
- Recurrent 'flash' pulmonary oedema with preserved LV function — suggests bilateral critical stenosis, a recognised revascularisation indication
- Steep creatinine rise (>30%) or AKI after starting ACEi/ARB — critical bilateral stenosis or stenosis to a solitary kidney
- Rapidly declining eGFR with a still-viable kidney — consider revascularisation
- Severe resistant hypertension despite >=3 agents including a diuretic
- Young woman with severe hypertension + abdominal bruit — FMD (angioplasty often curative)
Assessment
Differential diagnosis
- Essential/other secondary hypertension (primary aldosteronism, phaeochromocytoma, renal parenchymal disease)
- Hypertensive nephrosclerosis / CKD of other cause
- Atheroembolic (cholesterol embolism) renal disease (post-procedure, livedo, eosinophilia)
- Cardiac failure causing cardiorenal syndrome
- Thrombotic/thromboembolic renal artery occlusion (acute)
Investigations
- BP (often resistant), U&E/creatinine/eGFR (baseline + after RAS blockade), potassium (hypokalaemia from secondary hyperaldosteronism)
- Urinalysis (bland sediment), ACR
- Duplex ultrasound of renal arteries (first-line non-invasive; raised velocities, resistive index, size asymmetry)
- CT angiography or MR angiography (anatomy; avoid in advanced CKD/contrast concerns)
- Consider renal asymmetry (>1.5 cm) and the clinical triad; catheter angiography reserved for when intervention is planned (fibromuscular dysplasia angioplasty)
- Screen for FMD features in young hypertensives (abdominal/flank bruit, family history)
Management
- Suspect renovascular disease in: resistant/accelerated hypertension, hypertension onset <30 (FMD) or severe hypertension >55 with vascular disease, 'flash' pulmonary oedema, unexplained progressive CKD, significant creatinine rise after ACEi/ARB, or renal size asymmetry
- Optimise MEDICAL therapy as the default (ASTRAL/CORAL: routine stenting adds no benefit over medical therapy): BP control, cardiovascular risk reduction (statin, antiplatelet), smoking cessation, glycaemic control
- Use an ACEi or ARB for BP/renoprotection even in renovascular disease, but monitor U&E closely — a creatinine rise up to ~30% is acceptable; a larger rise suggests critical bilateral stenosis (or stenosis to a single functioning kidney) and the drug may need stopping
- Avoid ACEi/ARB in known bilateral critical stenosis / stenosis in a solitary kidney if it precipitates significant AKI
- Reserve revascularisation (angioplasty +/- stent for atherosclerotic; angioplasty for FMD) for selected patients: truly refractory hypertension despite maximal therapy, recurrent flash pulmonary oedema, or rapidly deteriorating renal function with viable kidney
- Treat FMD with angioplasty (often curative of hypertension) where significant and symptomatic
- Monitor renal function and BP long term; manage CKD complications per CKD pathway
Drugs & doses
Disposition
Complications & pitfalls
- Progressive ischaemic nephropathy / ESKD
- Resistant hypertension and its end-organ damage
- Flash pulmonary oedema / cardiac decompensation
- ACEi/ARB-precipitated AKI in bilateral/solitary-kidney disease
- Procedural risks of revascularisation (atheroembolism, restenosis, access complications)
Exam pearls
- A disproportionate creatinine rise (>30%) soon after starting an ACEi/ARB is the classic clue to significant (often bilateral) renal artery stenosis — investigate rather than simply blaming the drug.
- ASTRAL and CORAL showed routine stenting of atherosclerotic renal artery stenosis adds NO benefit over optimal medical therapy — medical management is the default; reserve intervention for refractory hypertension, flash pulmonary oedema or rapidly failing kidneys with a salvageable kidney [verify local/guideline criteria].
- Fibromuscular dysplasia is the exception: angioplasty is often curative of hypertension in young patients, so think FMD in a young hypertensive woman with an abdominal bruit.
- ACEi/ARB are still useful (and renoprotective) in most renovascular disease — just monitor renal function and avoid them when bilateral critical disease causes significant AKI.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.